OrbiMed’s Antares Pharma, Inc. ATRS Stock Holding History

OrbiMed’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-3,213,900	Closed	-$11.2M	–	147
2014 Q1	$11.2M	Sell	3,213,900 -1,378,100	-30%	-$6.11M	0.14%	88
2013 Q4	$20.5M	Buy	4,592,000 +227,000	+5%	+$925K	0.3%	63
2013 Q3	$17.7M	Sell	4,365,000 -4,834,000	-53%	-$21.1M	0.32%	58
2013 Q2	$38.3M	Buy	+9,199,000	New	+$35.5M	0.81%	34

Other funds holding ATRS

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

WHI

William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

OrbiMed's ATRS Position: Q2 2014 in Review

OrbiMed sold out of Antares Pharma, Inc. (ATRS) in Q2 2014, closing a stake of 3,213,900 shares — an estimated $11.2M sold.

OrbiMed first reported a position in ATRS in Q2 2013 and held it in 4 quarters. The position peaked at $38.3M in Q2 2013. 85 funds tracked by Wall St. Rank hold ATRS as of Q2 2014.

OrbiMed reported no remaining Antares Pharma, Inc. position as of Q2 2014 after selling out during the quarter.
OrbiMed sold 3,213,900 Antares Pharma, Inc. shares in Q2 2014, an estimated $11.2M.
OrbiMed first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 4 quarters.
OrbiMed's Antares Pharma, Inc. position peaked at $38.3M in Q2 2013.
85 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2014.

Based on OrbiMed's 13F filing for Q2 2014, filed 14 Aug 2014.